Ознакомительная версия. Доступно 28 страниц из 137
Gubler A. Alternating hemiplegia, a sign of pontine lesion, and documentation of the proof of the facial decussation / Wolf J. K. (ed.). The Classical Brainstem Syndromes. Springfield: Charles C Thomas, 1971. P. 9–13.
Austin S. C., Stolley P. D., Lasky T. The history of malariotherapy for neurosyphilis // JAMA. 1992. Vol. 268. № 4. P. 516–519.
Valenstein E. S. Great and desparate cures: The rise and decline of psychosurgery and other radical treatments for mental illness. New York: Basic Books, 1986.
EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial // The New England journal of medicine. 1985. November 7. Vol. 313. № 19. P. 1191–1200.
Echt D. S., Liebson P. R., Mitchell L. B. et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Supression Trial // The New England journal of medicine. 1991. March 21. Vol. 324. № 12. P. 781–788.
Moore T. J. Deadly Medicine: Why tens of thousands of heart patients died in america’s worst drug disaster. New York: Simon and Schuster, 1995.
Teo K. K., Yusuf S., Furberg C. D. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized trials // JAMA. 1993. October 6. Vol. 270. № 13. P. 1589–1595.
Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? // Lancet. 1995. June 10, Vol. 345. № 8963. P. 1455–1463.
Morgan D. J., Brownlee S., Leppin A. L., Kressin N., Dhruva S. S., Levin L. et al. Setting a research agenda for medical overuse // BMJ. 2015. August 25. Vol. 351. № 1, h4534.
Spencer I. Lessons from history: the politics of psychiatry in the USSR // Journal of Psychiatric and Mental Health Nursing. 2000. August. Vol. 7. № 4. P. 355–361.
Bloch S. Psychiatry as ideology in the USSR // Journal of medical ethics. 1978. Vol. 4. P. I26–13I.
Cochrane A. L., St Leger A. S., Moore F. Health service ‘input’ and mortality ‘output’ in developed countries // Journal of epidemiology and community health. 1978. September. Vol. 32. № 3. P. 200–205.
Carr-Hill R. A., Hardman G. F., Russell I. T. Variations in avoidable mortality and variations in health care resources // Lancet. 1987. April 4. Vol. 1. № 8536. P. 789–792.
Metcalfe D., Chowdhury R., Salim A. What are the consequences when doctors strike? // BMJ. 2015. November 25. Vol. 351. № 8035, h6231.
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 // Lancet. 2015. January 10. Vol. 385. № 9963. P. 117–171.
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 // Lancet. 2015. August 22. Vol. 386. № 9995. P. 743–800.
Kelly W. N. Can the frequency and risks of fatal adverse drug events be determined? // Pharmacotherapy. 2001. May. Vol. 21. № 5. P. 521–527.
Lazarou J., Pomeranz B. H., Corey P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analyses of prospective studies // JAMA. 1998. April 15. Vol. 279. № 15. P. 1200–1205.
Starfield B. Is US health really the best in the world? // JAMA. 2000. July 26. Vol. 284. № 4. P. 483–485.
Phillips D. P., Christenfeld N., Glynn L. M. Increase in US medication-error deaths between 1983 and 1993 // Lancet. 1998. February 28. Vol. 351. № 9103. P. 643–644.
Klevens R. M., Edwards J. R., Richards C. L., Horan T. C., Gaynes et al Estimating healthcare-associated infections and deaths in U. S. hospitals, 2002 // Public Health Reports. 2007. March-April. Vol. 122. № 2. P. 160–166.
Ernst F. R., Grizzle A. J. Drug-related morbidity and mortality: updating the cost-of-illness model // Journal of the American Pharmaceutical Association. 2001. March/April. Vol. 41. № 2. P. 192–199.
Johnson J. A., Boatman L. Drug-related morbidity and mortality: A Cost-of-illness model // Journal of Managed Care Pharmacy. 1996. January/February. Vol. 2. № 1. P. 39–47.
Sturkenboom M. C., Romano F., Simon G., Correa-Leite M. L., Villa M. et al. The iatrogenic costs of NSAID therapy: a population study // Arthritis and rheumatism. 2002 April 15. Vol. 47. № 2. P. 132–140.
Weingart S. N., Wilson R. McL., Gibberd R. W., Harrison B. Epidemiology of medical error // BMJ. 2000. March 18. Vol. 320. № 7237. P. 774–777.
Hayward R. A., Hofer T. P. Estimating hospital deaths due to medical errors: preventability is in the eye of the reviewer // JAMA. 2001. Vol. 286. № 4. P. 415–420.
Feldman H. A., Goldstein I., Hatzichristou D. G., Krane R. J., McKinlay J. B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study // The Journal of urology. 1994. January. Vol. 151. № 1. P. 54–61.
Araujo A. B., Johannes C. B., Feldman H. A., Derby C. A., McKinlay J. B. Relation between psychosocial risk factors and incident erectile dysfunction: prospective results from the Massachusetts male aging study // American Journal of Epidemiology. 2000. September 15. Vol. 152. № 6. P. 533–541.
Lexchin J. Bigger and better: how Pfizer redefined erectile dysfunction // PLoS Medicine. 2006. Vol. 3. № 4, e132.
Sample I. Viagra: The profitable pill // The Guardian. 2009. November 16.
Moynihan R. The making of a disease: female sexual dysfunction // BMJ. 2003. January 4. Vol. 326. № 7379. P. 45–47.
Critser G. Generation Rx: How prescription drugs are altering American lives, minds, and bodies. Boston: Houghton-Mifflin, 2005.
Laumann E. O., Paik A., Rosen R. C. Sexual dysfunction in the United States: prevalence and predictors // JAMA. 1999. Vol. 281. № 6. P. 537–544.
Moynihan R., Heath I., Henry D. Selling sickness: the pharmaceutical industry and disease mongering // BMJ. 2002. April 13. Vol. 324. № 7342. P. 886–891.
Clark D. Between hope and acceptance: the medicalisation of dying // BMJ. 2002. April 13. Vol. 324. № 7342. P. 905–907.
Gilbert D., Walley T., New B. Lifestyle medicines // BMJ. 2000. November 25. Vol. 321. № 7272. P. 1341–1344.
Maggini M., Vanacore N., Raschetti R. Cholinesterase inhibitors: drugs looking for a disease? // PLoS Medicine. 2006. Vol. 3. № 4, e140.
Ознакомительная версия. Доступно 28 страниц из 137
